ClinicalTrials.gg

Program

nilotinib

Also written as “Nilotinib”, “AMN107” and “Tasigna”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Neoplasms · Leukemia, Myeloid, Chronic-Phase · Leukemia, led by 3 companies.

Furthest: phase 4, since Sep 19, 200857 company-led studies, 1 open or runningNext primary completion: Aug 30, 2030 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis541 open or runningphase 4since Sep 19, 2008May 2, 2005Aug 30, 2030phase 4 · NCT04877522
Xspray Pharma AB20 open or runningphase 1since Jul 29, 2025Jul 29, 2025none ahead
XSpray Microparticles10 open or runningphase 1since Feb 19, 2014Feb 19, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since May 2, 2005.

  1. Nov 14, 2012Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01735955 · 57 enrolled · United States, Austria, Canada and more
  2. Dec 4, 2012Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01743989 · 620 enrolled · Austria, Belgium, Bulgaria and more
  3. Dec 5, 2012Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01744665 · 59 enrolled · United States
  4. Jan 30, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01784068 · 215 enrolled · United States, Argentina, Austria and more
  5. Apr 29, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01844765 · 59 enrolled · United States, France, Hungary and more
  6. May 23, 2013Phase 2 study in Gastrointestinal Stromal TumorsNovartis · NCT01863745 · 15 enrolled · Japan
  7. Feb 19, 2014XSpray Microparticles's first study: phase 1 study in HealthyNew to XSpray MicroparticlesXSpray Microparticles · NCT02068898 · 27 enrolled · United Kingdom
  8. Apr 7, 20142 phase 3 studiesNovartis · NCT02108951, NCT02115386
  9. Sep 17, 2014Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT02253277 · 5 enrolled · Germany
  10. Oct 21, 2014Phase 3 study in LeukemiaNovartis · NCT02272777 · 225 enrolled · China
  11. Sep 9, 2015Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT02546674 · 171 enrolled · Germany
  12. Mar 5, 2019Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT03874858 · 135 enrolled · Italy
  13. May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522 · 347 planned · United States, Argentina, Austria and more
  14. Jul 29, 2025Xspray Pharma AB's first studies: 2 phase 1 studies in NeoplasmsNew to Xspray Pharma ABXspray Pharma AB · NCT07138378, NCT07138352

Ahead

  1. Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522

TargetBeta

ABL1 →BCR →read by rule
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
EmbibatinibHansoh Pharmaceutical Groupphase 37
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 57 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07138378Neoplasms · India1CompletedXspray Pharma ABDec 15, 2024128
NCT07138352Neoplasms · United States1CompletedXspray Pharma ABJan 8, 202548
NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more4RecruitingNovartisAug 30, 2030347
NCT03874858Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Italy2TerminatedNovartisOct 15, 2025135
NCT02546674Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany4CompletedNovartisFeb 23, 2021171
NCT02272777Leukemia · China3CompletedNovartisJan 30, 2017225
NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedNovartisMar 6, 20185
NCT02115386Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation3TerminatedNovartisOct 31, 20167
NCT02108951Leukemia · Australia3TerminatedNovartisAug 10, 201620
NCT02068898Healthy · United Kingdom1CompletedXSpray MicroparticlesMar 201427
NCT01863745Gastrointestinal Stromal Tumors · Japan2CompletedNovartisOct 2, 202315
NCT01844765Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Hungary and more2CompletedNovartisJun 1, 201659
NCT01784068Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more2CompletedNovartisMay 31, 2016215
NCT01744665Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States2CompletedNovartisSep 28, 201859
NCT01743989Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Austria, Belgium, Bulgaria and more3CompletedNovartisJul 8, 2020620
NCT01735955Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more4CompletedNovartisJul 7, 202357
NCT01698905Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more2CompletedNovartisNov 26, 2015163
NCT01605981Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil4WithdrawnNovartisJan 20170
NCT01368523Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Poland4CompletedNovartisJan 201019
NCT01289028Gastrointestinal Stromal Tumors · Germany, Italy3CompletedNovartisJul 2014125
NCT01275196Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China3CompletedNovartisOct 2014267
NCT01274351Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Turkey2CompletedNovartisAug 1, 2019112
NCT01279473Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan2CompletedNovartisDec 200942
NCT01254188Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Algeria, Argentina, Australia and more3CompletedNovartisNov 2014421
NCT01227577Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States4CompletedNovartisNov 2014128
NCT01223898Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany, United Kingdom1CompletedNovartisDec 201319
NCT01220648Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedNovartisJan 20144
NCT01206088CML · Korea, Republic of4CompletedNovartisSep 201293
NCT01179737Pulmonary Arterial Hypertension · United States, Canada, Germany and more2TerminatedNovartisJan 201323
NCT01131325Leukemia, Myeloid, Chronic-Phase · United States4TerminatedNovartisMay 12, 20113
NCT01126892Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Colombia, Venezuela3CompletedNovartisApr 20116
NCT01110668Gastrointestinal Stromal Tumors · Turkey2CompletedNovartisSep 20112
NCT01077544Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France, Italy, Netherlands and more1CompletedNovartisJul 1, 201515
NCT01061177Leukemia · Austria, Belgium, Bulgaria and more4CompletedNovartisJul 20141,090
NCT01043874Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan4CompletedNovartisDec 201345
NCT01028222Melanoma · United States, Argentina, Australia and more2CompletedNovartisDec 201455
NCT00980018Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada4CompletedNovartisDec 201252
NCT00802841Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Brazil, China and more3CompletedNovartisJul 2014191
NCT00786812Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil4CompletedNovartisJan 201289
NCT00785785Gastrointestinal Stromal Tumors · United States, Argentina, Austria and more3CompletedNovartisOct 2014644
NCT00760877Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Australia, Brazil and more3CompletedNovartisJul 2015207
NCT00756509Gastrointestinal Stromal Tumors · Finland, France, Germany and more4CompletedNovartisDec 18, 202434
NCT00751036Gastrointestinal Stromal Tumors · Argentina, Brazil, Canada and more3TerminatedNovartisAug 201294
NCT00718562Gastrointestinal Stromal Tumors · Japan2CompletedNovartisJul 201335
NCT00644878Leukemia, Myeloid, Chronic-Phase · United States2TerminatedNovartisMar 201218
NCT00633295Gastrointestinal Stromal Tumors · Israel2CompletedNovartisMay 20109
NCT00519090Leukemia, Myeloid · United States, Australia, Belgium and more3TerminatedNovartisOct 20086
NCT00471497Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more3CompletedNovartisSep 2, 2009846
NCT00471328Gastrointestinal Stromal Tumors · United States, Australia, Austria and more3CompletedNovartisAug 2008248
NCT00441155Gastrointestinal Stromal Tumors · United States, France, Italy1CompletedNovartisJan 201114
NCT00418769Healthy1CompletedNovartisAug 200624
NCT00418756Healthy1CompletedNovartisNov 200612
NCT00418626Healthy · United States1CompletedNovartisSep 200727
NCT00384228Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan2CompletedNovartisJan 200742
NCT00264160Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Israel3CompletedNovartisNov 200836
NCT00135005Gastrointestinal Stromal Tumors · United States, France, Germany and more1CompletedNovartisNov 200659
NCT00109707Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more2CompletedNovartisSep 2012507

How it is read

Names in the registry

  • “Nilotinib”, 35 entries
  • “nilotinib”, 9 entries
  • “AMN107”, 3 entries
  • “Tasigna”, 2 entries
  • “Nilotinib (AMN107)”, 2 entries

Codes read as this program: XS003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.